---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-315163"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-07-24T12:03:32+00:00"
generated_at: "2026-07-24T12:05:07.228481+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma and Menarini receive positive CHMP opinion for obicetrapib products in Europe

## Summary
- CHMP recommends marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib/ezetimibe FDC) for hypercholesterolemia.
- Recommendation based on Phase 3 BROADWAY, BROOKLYN, and TANDEM trials showing LDL-C reductions up to 40-50% vs placebo.
- European Commission final decision expected in 2H26; if approved, authorization applies across EU plus Iceland, Liechtenstein, Norway.
- Menarini holds exclusive European commercialization rights; NewAmsterdam eligible for tiered double-digit royalties and up to €833M in milestones.

## SEC filing metadata
- accession: 0001193125-26-315163
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-07-24T12:03:32+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/0001193125-26-315163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/nams-20260724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-315163
- JSON: https://secwatch.observer/filing/0001193125-26-315163.json
- Plain text: https://secwatch.observer/filing/0001193125-26-315163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.